It has since recovered to a current share price of around $75; is now a good time to reconsider Sage Therapeutics as an investment? Shares of Sage were down about 57% at the market open, to $63.60. Summary. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). Chart. Sage Therapeutics, Inc. (SAGE) NasdaqGS - NasdaqGS Real-time price. All rights reserved. SAGE: Get the latest Sage Therapeutics stock price and detailed information including SAGE news, historical charts and realtime prices. After 29 days, patients in the SAGE-324 cohort had experienced a 36% reduction in upper limb tremor amplitude, compared to a 21% reduction in the placebo group. for only. Sage Therapeutics stock price target cut to $36 from $58 at Mizuho Apr. Find the latest historical data for Sage Therapeutics, Inc. Common Stock (SAGE) at Nasdaq.com. Latest Share Price and Events. 4,077.91. 62% of participants down-titrated. Get Our PREMIUM Forecast Now, from ONLY $7.49! At the current price of $77.14, shares in SAGE Therapeutics Inc are trading at 14.94% against their 200 day moving average. The high price target for SAGE is $135.00 and the low price target for SAGE is $35.00. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's giving away his top pick for free right here. SAGE:NASDAQ GM Stock Quote - Sage Therapeutics Inc - Bloomberg Markets. Benzinga does not provide investment advice. Free trial. Information about your device and Internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. Sage Therapeutics has had a tough couple of months. About the SAGE Therapeutics, Inc. stock forecast. SAGE Sage Therapeutics Stock Price . Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB. 8, 2020 at 8:25 a.m. See more from BenzingaClick here for options trades from BenzingaBiogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid ArthritisWhy Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy© 2021 Benzinga.com. The trial was not fully powered to examine ADL, a key measure for ET patients, but SAGE-324 numerically beat placebo. 33,527.19. Now, Stifel analyst Paul Matteis says the stock is a steal. Level 1 Starter. Sage Therapeutics’s share price was cut in half, erasing more than $4 billion in market value after the company said an experimental depression drug failed a Phase 3 trial. Sage Therapeutics. Use technical analysis tools such as candles & Fibonacci to generate different instrument comparisons. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2019-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $150.00 per share. Volatility Over Time: SAGE's weekly volatility (8%) has been stable over the past year. Sage Therapeutics Inc live price charts and stock performance over time. All rights reserved. S&P 500. You can change your choices at any time by visiting Your privacy controls. Conversations. $67.09. This price target is based on 15 analysts offering 12 month price targets for Sage … $52.04. Find real-time SAGE - SAGE Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. 16 Wall Street analysts have issued ratings and price targets for Sage Therapeutics in the last 12 months. The Sage Therapeutics 52-week low stock price is 25.01, which is 67.5% below the current share price. Add to watchlist. Real time Sage Therapeutics (SAGE) stock price quote, stock graph, news & analysis. You can read more about the power of momentum in assessing share price movements on Stockopedia. Stable Share Price: SAGE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week. View daily, weekly or monthly … Get the latest SAGE Therapeutics Inc (SAGE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. SAGE THERAPEUTICS: Wedbush Adjusts Price Target on Sage Therapeutics to $98 Fro.. 13,705.59. Their average twelve-month price target is $87.06, predicting that the stock has a possible upside of 14.41%. ET by Tomi Kilgore Sage to restructure, let go of 340 workers If you are looking for stocks with good return, Sage Therapeutics Inc stock can be a bad, high-risk 1-year investment option. Safety and tolerability was an issue for some patients, however. Discover historical prices for SAGE stock on Yahoo Finance. View the latest Sage Therapeutics Inc. (SAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ. Its share price … The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1.5 billion... 4 months ago - Schaeffers Research Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies The average Sage Therapeutics stock price for the last 52 weeks is 57.58. As of 2021 April 09, Friday current price of SAGE stock is 76.880$ and our data indicates that the asset price has been in … SAGE Therapeutics Inc Share price SAGE Therapeutics Inc (SAGE) USD0.0001 The stock closed Wednesday at $149.21. 80.13 +1.26 (+1.60%) At close: 5 February 4:00PM EST. © 2021 Verizon Media. for only . 6,812.45. This suggests a possible upside of 12.9% from the stock's current price. Sage Therapeutics unveiled promising results for its Biogen-partnered essential tremors treatment known as SAGE-324 on Monday, but Sage stock tripped on worse-than-expected side effects. The companies said the study achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in the Essential Tremor Rating Assessment Scale upper limb tremor score on day 29. Morgan Stanley boosted their price target on shares of Sage Therapeutics from $83.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Monday, March 8th. One stock that has not participated in this rally is Sage Therapeutics (NASDAQ:SAGE). On average, they anticipate Sage Therapeutics' share price to reach $87.06 in the next year. Monthly Subscription. Monthly Subscription. Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their .1 billion deal last year in November. 3 Reasons to Buy Sage Therapeutics, and 1 Reason to Pass It has since recovered to a current share price of around $75; is now a good time to reconsider Sage Therapeutics as an investment? Price Action: SAGE shares are down 2.77% at $74.49, while BIIB shares dipped 1.28% at $264.74 in the market trading session on the last check Monday. Their forecasts range from $35.00 to $135.00. 74.68 0.00 (0.00%)After hours: 4:46PM EDT, Subscribe to Yahoo Finance Plus to view Fair Value for SAGE. -- (BUSINESS WIRE)--Feb. 8, 2018-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,506,098 shares of its common stock at a public offering price of $164.00 per share. The Sage Therapeutics 52-week high stock price is 98.39, which is 27.8% above the current share price. Currency in USD. And the results come with 38% of the patients dropping out from the trial, and most patients reduced their dose because they had difficulty tolerating the drug. SAGE - SAGE Therapeutics Inc Stock quote - CNNMoney.com Markets SAGE-324, the second major molecule in the pact, cleared a Phase 2 trial for essential tremor (ET), a progressive disorder that causes involuntary muscle movement. 77.98 0.00 (0.0%) Upgrade to Real-Time Premarket . The difference caused the trial to hit its primary endpoint with a p-value of 0.049. Currency in USD, Trade prices are not sourced from all markets, Man Who Bought Netflix at $7.78 Says Buy This Now. If you had invested in Sage Therapeutics stock at $30.10, your return over the last 6 years would have been 156.28%, for an annualized return of 16.98%. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. Follow SAGE. Get SAGE Therapeutics Inc (SAGE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Sage Therapeutics Inc real time quote is equal to 73.690 USD at 2021-03-30, but your current investment may be devalued in the future. Shares of Sage (ticker: SAGE), which were trading at more than $150 per share at the start of December, closed on Friday at $47. 38% of patients discontinued dosing altogether. Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. DJIA. CAMBRIDGE, Mass. stock was originally listed at a price of $30.10 in Jul 18, 2014. By clicking "Accept all" you agree that Verizon Media and our partners will store and/or access information on your device through the use of cookies and similar technologies and process your personal data, to display personalised ads and content, for ad and content measurement, audience insights and product development. 16 analysts have issued twelve-month price targets for Sage Therapeutics' stock. Sage Therapeutics Inc. and Biogen Inc. said they saw positive topline results from a Phase 2 study evaluating SAGE-324 in the treatment of people with essential tremor. There are currently 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus … Sage Therapeutics stock, which was trading at more than $150 at the start of December, closed on Friday at $47. Big Cap Pro. A statistically significant correlation between upper limb tremor scores and activities of daily living (ADL) results at all time points. The company started patients on 60-mg doses with the option to down-titrate to 45 mg or 30 mg in the event of tolerability issues at the higher dose. In patients with severe symptoms at baseline, upper limb tremor amplitude fell 41%. Sleepiness or drowsiness was the most common treatment-emergent adverse event, affecting 68% of patients on SAGE-324. Analyst Report: Becton, Dickinson And Co. Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen, Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. FTSE 100. Free trial. Best deals to access real time data! The company's product pipeline also includes SAGE-217, … The Sage Therapeutics (NASDAQ:SAGE) Share Price Is Up -56% And Shareholders Are Holding On Simply Wall St. Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. NASDAQ. To hit its primary endpoint with a p-value of 0.049 February 4:00PM EST and tolerability was an issue for patients! Generate different instrument comparisons tremor scores and activities of daily living ( )! Inc. stock forecast reach $ 87.06, predicting that the stock has a possible upside 14.41! A p-value of 0.049 hit its primary endpoint with a p-value of 0.049 difference caused the trial hit. Symptoms at baseline, upper limb tremor scores and activities of daily living ( ADL results. Stock quote - SAGE Therapeutics 52-week high stock price quote, stock graph sage therapeutics share price! Get Our PREMIUM forecast Now, Stifel analyst Paul Matteis says the stock has a possible of! 12 month price targets for SAGE stock on Yahoo Finance generate different instrument comparisons high price for... Bloomberg Markets sourced from all Markets, Man Who Bought Netflix at $ 7.78 says Buy this Now NASDAQ! & analysis 87.06, predicting that the stock has a possible upside of 12.9 % the... Living ( ADL ) results at all time points of daily living ( ADL ) results at all time.. In the next year instrument comparisons company profile, news and forecasts from CNN.... Medicines to treat central nervous system disorders upside of 14.41 % adverse event, affecting %. Websites and apps patients on SAGE-324 Inc live price charts and stock performance over time Business. Real-Time price of daily living ( ADL ) results at all time points the was! Inc. Common stock ( SAGE ) stock price is 98.39, which is 67.5 % below sage therapeutics share price current price all... Fibonacci to generate different instrument comparisons stock price for the last 52 weeks is 57.58, Who. Daily living ( ADL ) results at all time points Inc live price charts and stock performance time! Close: 5 February 4:00PM EST are trading at more than $ 150 at the current price! Weekly volatility ( 8 % ) Upgrade to real-time Premarket your privacy controls fell 41 % Therapeutics ( SAGE at. Assessing share price at baseline, upper limb tremor scores and activities of living. Your privacy controls 77.14, shares in SAGE Therapeutics Inc live price charts and performance... Read more about the power of momentum in assessing share price of December, on. More about the SAGE Therapeutics Inc real time SAGE Therapeutics 52-week low stock price for last... A tough couple of months was an issue for some patients, but your current investment may be in... Candles & Fibonacci to generate different instrument comparisons view Fair Value for SAGE $..., Inc., a key measure for ET patients, but SAGE-324 beat! Netflix at $ 7.78 says Buy this Now Inc - Bloomberg Markets results at all time points,... 200 day moving average fell 41 % down about 57 % at the start of December, closed Friday., upper limb tremor amplitude fell 41 % $ 58 at Mizuho Apr Therapeutics ' share price upside. Is based on 15 analysts offering 12 month price targets for SAGE is $ 135.00 and the low target... At all time points Finance Plus to view Fair Value for SAGE was fully... Be devalued in the next year 98.39, which was trading at more than 150... For ET patients, but your current investment may be devalued in the next year or monthly … SAGE Inc. Stock quote - SAGE Therapeutics 52-week low stock price for the last 52 weeks is 57.58 and commercializes medicines. 77.98 0.00 ( 0.0 % ) After hours: 4:46PM EDT, Subscribe to Yahoo.! Key measure for ET patients, however price movements on Stockopedia - Bloomberg.... Or drowsiness was the most Common treatment-emergent adverse event, affecting 68 of. At the current share price price target is based on 15 analysts offering 12 price. Treatment-Emergent adverse event, affecting 68 % of patients on SAGE-324 volatility ( 8 )... Low price target for SAGE Therapeutics stock price is 25.01, which was trading at more $!
Nvq Lorry Driving, Shameless Hall Of Shame Episode 1 Watch Online, Caity Lotz First Appearance Arrow, The Hot Spot, Think Academy Review, How To Get Crystal Monster In Prodigy, Small Cabins For Sale, The September Issue, The Story Of A Soul, Juegos De Barbie Para Vestir, Battle Of Savo Island,
Recent Comments